We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Single Automated Analyzer to Bring Full Suite of Diagnostics to Wherever Patients Are

By HospiMedica International staff writers
Posted on 04 May 2023
Image: The single automated device can run hematology, clinical chemistry, and immunoassays subsystems in parallel (Photo courtesy of Freepik)
Image: The single automated device can run hematology, clinical chemistry, and immunoassays subsystems in parallel (Photo courtesy of Freepik)

Timely and accurate diagnostics can enhance patient care by making it more informed, personalized, and proactive. Now, a novel platform that delivers swift results using minimal blood volumes incorporates technology that facilitates automation and adaptable form factors outside centralized labs, bridging the gap between diagnostics and treatment.

Vital Biosciences Inc. (Mississauga, ON, Canada) is developing a single automated device designed to provide a comprehensive range of diagnostics directly to patients. The company's technology strives to make healthcare significantly more personalized, proactive, and accessible. With only 600 uL of blood, the platform can measure 50+ of the most commonly requested biomarkers in primary care within 20 minutes, without compromising analytical performance. The instrument employs an automated microfluidic workflow to simultaneously run three subsystems: hematology, clinical chemistry, and immunoassays. The platform quantifies the complete panel of biomarkers using on-board optical readers and automated sample preparation and measurement procedures that require minimal user input. This makes the platform suitable for use in CLIA-waived settings.

Vital's initial menu caters to a broad range of potential use cases for the general population, including inflammation, cardiac markers, diabetes, liver disorders, lipid disorders, post-acute event monitoring, clinical trial monitoring, chronic disease management, and proactive lifestyle management. The company aims to create a comprehensive menu that covers 100% of the tests needed for at least 90% of patients, thereby eliminating the need to send tests to a centralized lab. Patients would no longer need to travel to a draw site or ship their samples to a centralized laboratory, nor wait for days to discuss their results with their healthcare provider. Patients who are likely to require bloodwork can provide their sample at check-in and receive results during their initial appointment. Bridging this care gap will make diagnostics more accessible and accelerate clinical decision-making.

Related Links:
Vital Biosciences Inc. 

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
12-Channel ECG
CM1200B
New
Medical Examination & Procedure Light
Vega 80
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor

Channels

Critical Care

view channel
Image: The nasal spray is created using the ‘Nano-in-Micron’ technology platform. The micron-sized powder is inhaled and travels along the nose-to-brain pathway, bypassing the blood-brain barrier to deliver the drug directly to the brain (Photo courtesy of The University of Hong Kong

New Nasal Spray Enables Prehospital Neuroprotection in Ischemic Stroke

Ischemic stroke, caused by arterial occlusion in the brain, requires time‑critical intervention to limit neuronal loss. Many patients arrive outside the narrow window for thrombolysis or thrombectomy,... Read more

Surgical Techniques

view channel
Image: MUSA-3 is designed to assist surgeons during open super‑microsurgical procedures by downscaling and stabilizing hand movements (Photo courtesy of Microsure)

Robotic Microsurgery System Gains CE Mark for Clinical Use in Europe

Microsure (Eindhoven, The Netherlands) announced on May 7, 2026 that its MUSA-3 system received CE mark approval, enabling clinical use in Europe. The milestone marks the company’s transition from product... Read more